Table 2. Clinical, laboratory and outcome findings of patients treated in ICU with COVID-19.
Abbreviations: COVID 19, Corona Virus Disease 2019 caused by SARS-CoV-2; ICU, intensive care unit; NOAF, new onset atrial fibrillation; IQR, interquartile range; AKI, acute kidney injury; RRT, renal replacement therapy; LV, left ventricle; LVSD, left ventricular systolic dysfunction; ECMO, ;d, days.
Data are presented as n (%), or n/N (%) unless specified as median (IQR). P values indicate difference between patients with NOAF and those without NOAF in ICU. P<0.05 was considered statistically significant.
*Echocardiography was only performed in 90 patients (16 NOAF group and 74 without NOAF group) and the percentage is expressed accordingly.
** Therapeutic anticoagulation commenced in some patients with high thrombotic risk based on clinical assessment and with extremely elevated D-Dimer levels in the context of COVID-19 (7 patients).
| Normal range | Total (N=109) | With NOAF during ICU stay (n=16) | Without NOAF during ICU stay (n=93) | P value | |
|---|---|---|---|---|---|
| Clinical findings during ITU admission with COVID-19 | |||||
| Acute kidney injury(AKI) | 70(64) | 15(94) | 55(59) | 0.028 | |
| AKI not requiring RRT | 31(28) | 7(44) | 24(26) | -- | |
| Severe AKI requiring RRT | 39(36) | 8(50) | 31(33) | -- | |
| Echocardiography findings* | |||||
| LV systolic function,median,(IQR),% | >55 | 60(55-65) | 60(55-60) | 60(55-65) | 0.36 |
| Good LV systolic function≥55% | 83(92) | 15(94) | 68(92) | -- | |
| Mild LVSD with EF 45-54% | 2(2) | 0(0) | 2(2) | -- | |
| Moderate LVSD with EF 36-44% | 5(5) | 1(6) | 4(5) | -- | |
| Severe LVSD with EF≤35% | 1(1) | 0(0) | 1(1) | -- | |
| Left atrial size | 0.1 | ||||
| Normal | 60(67) | 7(44) | 53(71) | -- | |
| Mildly enlarged | 27(30) | 8(50) | 19(26) | -- | |
| Moderately enlarged | 3(3) | 1(6) | 2(2) | -- | |
| Laboratory findings during ITU admission with CoVID-19 -Median,(IQR) | |||||
| White blood cell countx109/L | 4.0-10.0 | 18(14.0-25.5) | 18(13-30) | 18(14-24) | 0.73 |
| C-Reactive Protein mg/L | <3.0 | 333(256-388) | 324(248-400) | 333(256-388) | 0.8 |
| Ferritin ug/L | 41-400 | 1870(1078-2904) | 1670(1128-2329) | 1926(1031-3018) | 0.45 |
| Creatinine Kinase unit/L | 40-320 | 608(279-1677) | 1460(350-2325) | 583(272-1593) | 0.2 |
| Troponin T ng/L | <14 | 80(35-160) | 83(53-158) | 80(33-160) | 0.5 |
| D Dimer mg/L | 0-0.5 | 17(6-59) | 18(8-46) | 17(6-60) | 0.9 |
| Complications and outcome | |||||
| ECMO support | 12(11) | 2(13) | 10(11) | 0.83 | |
| Venous thromboembolism | 21(19) | 4(25) | 17(18) | 0.54 | |
| Arterial embolism | 3(3) | 1(6) | 2(2) | 0.36 | |
| Therapeutic Anticosgulation | 0.8 | ||||
| New onset AF | 2(2) | 2(12.5) | 0(0) | -- | |
| Venous/arterial thromboembolism | 24(22) | 5(31) | 19(20) | -- | |
| Hypercoagulable state** | 7(6) | 0(0) | 7(8) | -- | |
| Length of stay in ICU median,(IQR),d | |||||
| Survivors | 35(22-42) | 42(37-44) | 32(21-40) | 0.03 | |
| Non survivors | 17(12-22) | 18(12-26) | 15(12-21) | 0.39 | |
| In hospital death | 38(35) | 11(69) | 27(29) | 0.002 |